Still disappointing that apceth have decided to shift its focus to non-malignant cancers.
I hope Cynata and Ross have seen the following report:
https://globenewswire.com/news-release/2016/05/03/835853/0/en/Global-Cancer-Stem-Cell-Therapy-Market-Outlook-2020-Clinical-Pipeline-by-Company-Phase.html
Is says “Cancer stem cell therapies are also expected to be developed withhelp. They are expected to have superior therapeutic effects as compared to conventional therapeutics. With time, mass production is also expected to improve with improve in technology. Higher production at lower cost will allow the pharmaceutical companies to gain more market shares.”
Cynata should be getting mentioned in these types of reports for its mass production technology. Presently it’s not!
The report also identifies another 22 competitor to apceth in this space. I wonder how many of them have heard of Cynata’s proprietary Cymerus™ mesenchymal stem cell (MSC) technology?
Still disappointing that apceth have decided to shift its focus...
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CYP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
25.5¢ |
Change
0.005(2.00%) |
Mkt cap ! $45.80M | |||
| Open | High | Low | Value | Volume |
| 25.5¢ | 25.5¢ | 25.5¢ | $313 | 1.229K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 22209 | 25.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 26.0¢ | 36715 | 1 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| CYP (ASX) Chart |